Pheast Therapeutics

About:

Pheast Therapeutics develops checkpoint therapies to harness the innate immune system.

Twitter/X: pheast_inc

Top Investors: ARCH Venture Partners, Catalio Capital Management, Alexandria Venture Investments, Risk & Reward Group

Description:

Pheast Therapeutics is a cancer immunotherapy company focused on developing novel checkpoint therapies to harness the innate immune system in the fight against cancer. It was founded in 2020 and headquartered in Palo Alto, California.

Total Funding Amount:

$76M

Headquarters Location:

Palo Alto, California, United States

Founded Date:

2020-01-01

Founders:

Amira Barkal, Roy Maute

Number of Employees:

11-50

Last Funding Date:

2022-04-26

IPO Status:

Private

Industries: